GSK statement on Avodart™ (dutasteride) for prostate cancer risk reduction
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced that it will no longer pursue global approval (marketing authorisation) for the use of Avodart™ (dutasteride) to reduce the risk of prostate cancer.
Novartis completes acquisition of majority stake in Zhejiang Tianyuan expanding vaccines presence in China
- Details
- Category: Novartis
Novartis completed the transaction to acquire an 85 percent stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. This acquisition provides Novartis with an expanded presence in the Chinese vaccines market
Sanofi-aventis Strengthens Commitment to Ophthalmology through Partnership with The Vision Institute
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced the official signing of a cooperation agreement between Fovea Pharmaceuticals, its Ophthalmology Division, and the Vision Institute, one of the main eye disease research centers in Europe, for research in the diagnosis, prevention and treatment of ocular diseases.
SPIRIVA HandiHaler Prolonged Time To First COPD Exacerbation
- Details
- Category: Pfizer
A new study showed that SPIRIVA® HandiHaler® (tiotropium bromide inhalation powder), a long-acting anticholinergic, was significantly more effective at preventing Chronic Obstructive Pulmonary Disease (COPD) exacerbations than salmeterol HFA-MDI (hydrofluororalkane-metered dose inhaler).
Roche announces positive pivotal Phase II results for Hedgehog Pathway Inhibitor
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib (RG3616/GDC-0449), showed positive results in people with advanced basal cell carcinoma (aBCC), a particularly severe and debilitating form of skin cancer.
Phase III Study of Investigational Compound Ipilimumab Achieves Primary Endpoint
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) today announced that a clinical trial - known as study 024 - of its investigational compound ipilimumab has met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma.
Novartis receives European Commission approval for Gilenya®
- Details
- Category: Novartis
The European Commission has granted Novartis approval for Gilenya® (fingolimod) 0.5 mg daily as a disease modifying therapy in patients with highly active relapsing-remitting multiple sclerosis (RRMS) despite treatment with beta interferon, or in patients with rapidly evolving severe RRMS.
More Pharma News ...
- GSK supports recovery efforts to help those affected by the Japan earthquake
- Novartis committed to provide equivalent of more than USD 3 million in relief aid to Japan earthquake victims
- MorphoSys Signs Manufacturing Agreement with Boehringer Ingelheim
- NAFE Names Lilly to Top 50 Companies for Executive Women
- GSK announces positive topline results of Phase lll study of IPX066 in advanced Parkinson's disease
- Amgen Donates $1 Million to Help Japanese Disaster Victims
- Abbott Supports Relief Efforts in Japan